Equities analysts forecast that Allakos Inc (NASDAQ:ALLK) will report earnings of ($0.50) per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Allakos’ earnings, with the lowest EPS estimate coming in at ($0.50) and the highest estimate coming in at ($0.49). Allakos posted earnings per share of ($0.35) during the same quarter last year, which would suggest a negative year-over-year growth rate of 42.9%. The company is expected to issue its next earnings results on Thursday, March 12th.
On average, analysts expect that Allakos will report full year earnings of ($1.88) per share for the current fiscal year, with EPS estimates ranging from ($1.88) to ($1.87). For the next year, analysts anticipate that the business will report earnings of ($2.58) per share, with EPS estimates ranging from ($2.98) to ($2.17). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Allakos.
Allakos (NASDAQ:ALLK) last issued its earnings results on Tuesday, November 12th. The company reported ($0.47) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by ($0.04).
Shares of NASDAQ ALLK traded down $7.16 during midday trading on Tuesday, hitting $115.90. 608,969 shares of the company’s stock were exchanged, compared to its average volume of 449,455. The firm’s fifty day simple moving average is $80.42 and its 200-day simple moving average is $64.83. The company has a market cap of $6.70 billion, a PE ratio of -52.68 and a beta of -1.13. Allakos has a twelve month low of $30.32 and a twelve month high of $139.99.
A number of hedge funds and other institutional investors have recently modified their holdings of ALLK. Tower Research Capital LLC TRC bought a new position in Allakos in the 3rd quarter valued at about $42,000. Bank of Montreal Can bought a new position in shares of Allakos in the second quarter valued at approximately $63,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Allakos during the third quarter worth $113,000. Amundi Pioneer Asset Management Inc. purchased a new stake in Allakos in the 1st quarter valued at $142,000. Finally, Metropolitan Life Insurance Co NY grew its stake in shares of Allakos by 66.5% in the 1st quarter. Metropolitan Life Insurance Co NY now owns 4,931 shares of the company’s stock worth $199,000 after acquiring an additional 1,970 shares in the last quarter. 68.68% of the stock is currently owned by hedge funds and other institutional investors.
Allakos Company Profile
Allakos Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis.
Featured Article: The role of implied volatility with call option volume
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Allakos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allakos and related companies with MarketBeat.com's FREE daily email newsletter.